IMPEDIMED LIMITED — Director's Dealing 2020

Nov 15, 2020

==> picture [129 x 31] intentionally omitted <==

16 November 2020

ASX ANNOUNCEMENT

Revised Appendix 3Y

Brisbane, Australia – Attached is a revised Appendix 3Y for Mr Carreon, with the date of change on the document modified correctly to ‘November’ from ‘October’.

Approved for release by the Company Secretary.

Contact Details

Investor Relations Contact: Media Contact: Mike Bassett, ImpediMed Kyahn Williamson, WE Buchan T : +61 407 431 432 T: +61 3 9866 4722 E: mbassett@impedimed.com E: kwilliamson@we-worldwide.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health .

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO[®] for multiple indications including heart failure, lymphoedema, body composition, and protein calorie malnutrition, sold in select markets globally.

For more information, visit www.impedimed.com.

About SOZO Digital Health Platform

SOZO, the world’s most advanced, noninvasive bioimpedance spectroscopy (BIS) device, delivers a precise snapshot of fluid status and tissue composition in less than 30 seconds. Using ImpediMed’s BIS technology, SOZO measures 256 unique data points over a wide spectrum of frequencies from 3 kHz to 1000 kHz. Results are available immediately online for easy data access and sharing across an entire healthcare system. The FDA-cleared, CE-marked and ARTG-listed digital health platform aids in the early detection of secondary lymphoedema, provides fluid status for patients living with heart failure, and can be used to monitor and maintain overall health – all on a single device.

For more information, visit: https://www.impedimed.com/products/sozo/.

About SOZO Fluid Analysis for Lymphoedema

The SOZO fluid analysis for lymphoedema provides the L-Dex score to measure fluid buildup in a limb at risk for lymphoedema. By identifying the patient’s baseline L-Dex score before cancer treatment and then measuring it at regular intervals post-treatment, healthcare professionals can accurately and objectively monitor patient progress and offer appropriate education and intervention to prevent the progression of lymphoedema. 1-year interim results from the PREVENT Trial showed that this early detection combined with athome intervention using standard compression therapy can reduce the progression of lymphoedema by 95%. Use of L-Dex and BIS for the clinical assessment of lymphoedema is recommended in multiple clinical practice guidelines including the American Physical Therapy Association, National Lymphedema Network, and Lymphatic Education & Research Network Centers of Excellence program.

For more information, visit: https://www.impedimed.com/healthcare/cancer-relatedlymphedema/

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: ImpediMed Limited ABN: 089 705 144

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Richard Carreon
Date of last notice	06 July 2020

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.
Date of change	10 November 2020
No. of securities held prior to change	2,376,259 Ordinary Shares 15,648,484 Options 3,224,871 Performance Rights
Class	Ordinary Shares
Number acquired	1. 262,262 Ordinary Shares 2. 6,159,000 Options 3. 7,400,000 Performance Rights
Number disposed	Nil

• See chapter 19 for defined terms.

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	1. $0.079 per share 2. Nil 3. Nil
No. of securities held after change	2,638,521 Ordinary Shares 21,807,484 Options 10,624,871 Performance Rights
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	1. Issue of shares in lieu of base remuneration for quarter ended 30 June 2020. 2. Grant of Options. 3. Grant of Performance Rights.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract Nature of interest Name of registered holder (if issued securities) Date of change No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired Interest disposed Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation Interest after change

• See chapter 19 for defined terms.

Appendix 3Y Page 2

Appendix 3Y Change of Director’s Interest Notice

Part 3 –[+] Closed period

Part 3 –+Closed period
Were the interests in the securities or contracts detailed above traded during a+closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?
If prior written clearance was provided, on what date was this provided?

Date of Notice: 10 November 2020

• See chapter 19 for defined terms.

Appendix 3Y Page 3